Hydrea (Hydroxycarbamide)

Hydrea is indicated for several hematologic disorders and selected malignancies, where inhibition of DNA synthesis helps control abnormal cell proliferation and improve disease‑related outcomes.

• Chronic myelogenous leukemia (CML): used as part of therapy to suppress leukemic cell growth.
• Sickle cell disease: administered to increase fetal hemoglobin and lower the rate of vaso‑occlusive episodes.
• Polycythemia vera: helps reduce elevated red blood cell mass.
• Essential thrombocythemia: used to control excessive platelet production.
• Other myeloproliferative neoplasms: may be employed when standard therapies are insufficient.

• Hydroxyurea, the active component of Hydrea, competitively inhibits the enzyme ribonucleotide reductase, which is essential for converting ribonucleotides to deoxyribonucleotides. By limiting the pool of deoxyribonucleotides, the drug impairs DNA synthesis and repair, preferentially affecting rapidly dividing cells such as malignant leukocytes and erythroid precursors. This inhibition also leads to increased production of fetal hemoglobin in sickle cell disease, contributing to its therapeutic effect.

Like many antineoplastic agents, Hydrea may cause a range of adverse reactions, which are generally categorized by frequency and severity. These reactions can vary in intensity and may require monitoring or medical intervention.

Common

• Nausea, vomiting, or mild gastrointestinal upset
• Decreased appetite and weight loss
• Transient reduction in white blood cells (leukopenia) or platelets (thrombocytopenia)
• Skin changes such as darkening or hyperpigmentation, especially on the face or hands

Serious

• Significant bone marrow suppression causing anemia, neutropenia, or severe thrombocytopenia
• Acute kidney injury or worsening renal function
• Severe hypersensitivity reactions, including Stevens‑Johnson syndrome or toxic epidermal necrolysis

Hydrea requires careful patient assessment and ongoing monitoring because of its potential impact on blood counts, organ function, and reproductive health.

• Baseline and periodic complete blood counts to detect bone marrow suppression.
• Regular renal and hepatic function tests, especially in patients with pre‑existing impairment.
• Contraindicated in pregnancy; women of childbearing potential must use effective contraception.
• Caution in patients with a history of severe hypersensitivity or skin reactions.
• Dose adjustments may be needed for elderly patients or those with reduced kidney function.
• Avoid use in individuals with active infections until resolved.
• Monitor for signs of fetal hemoglobin increase in sickle cell disease therapy.

Hydroxyurea can interact with other medicines, affecting its efficacy or increasing toxicity; awareness of key interactions helps optimize safety.

Avoid

• Concurrent use with other myelosuppressive agents (e.g., azacitidine, cytarabine) that may exacerbate bone marrow depression.
• Live vaccines while on therapy, due to impaired immune response.

Use with caution

• Antiretroviral drugs such as zidovudine, which may increase hematologic toxicity.
• NSAIDs or aspirin, which can heighten the risk of gastrointestinal bleeding.
• Drugs that affect renal clearance (e.g., probenecid) may alter hydroxyurea levels.
• Phenytoin or other enzyme‑inducing anticonvulsants that could reduce hydroxyurea exposure.